Pain Management and the Opioid Epidemic


Book Description

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.




Prescription Drug Abuse and Diversion


Book Description




How Do Prescription Drug Monitoring Programs Reduce Opioid Prescribing?


Book Description

Past work demonstrates that mandated prescription drug monitoring programs (PDMPs) decrease opioid prescribing, but provides limited evidence on mechanisms. We analyze Kentucky's landmark PDMP mandate to disentangle the role of information versus hassle costs. PDMP mandates are meant to affect prescribing through information provision but may also unintentionally affect prescribing through the hassle cost of required record checks. On net, we find that although information clearly affected prescribing, hassle costs explain the majority of the decline in prescribing from this program. Hassle costs, however, did not deter physicians from prescribing opioids to the patients who would benefit the most.




How Do Prescription Drug Monitoring Programs Reduce Opioid Prescribing? The Role of Hassle Costs Versus Information


Book Description

Past work demonstrates that mandated prescription drug monitoring programs (PDMPs) decrease opioid prescribing, but provides limited evidence on mechanisms. We analyze Kentucky's landmark PDMP mandate to disentangle the role of information versus hassle costs. PDMP mandates are meant to affect prescribing through information provision but may also unintentionally affect prescribing through the hassle cost of required record checks. On net, we find that although information clearly affected prescribing, hassle costs explain the majority of the decline in prescribing from this program. Hassle costs, however, did not deter physicians from prescribing opioids to the patients who would benefit the most.




Factorial Survey Experiments


Book Description

Filling a gap in the literature of the field, Factorial Survey Experiments provides researchers with a practical guide to using the factorial survey method to assess respondents’ beliefs about the world, judgment principles, or decision rules through multi-dimensional stimuli (“vignettes”) that resemble real-life decision-making situations. Using insightful examples to illustrate their arguments, authors Katrin Auspurg and Thomas Hinz guide researchers through all relevant steps, including how to set up the factorial experimental design (drawing samples of vignettes and respondents), how to handle the practical challenges that must be mastered when an experimental plan with many different treatments is embedded in a survey format, and how to deal with questions of data analysis. In addition to providing the “how-tos” of designing factorial survey experiments, the authors cover recent developments of similar methods, such as conjoint analyses, choice experiments, and more advanced statistical tools.




Prescription Drug Monitoring Programs and Opioid Poisoning


Book Description

Introduction: Prescription drug monitoring programs (PDMPs) are one strategy established to curb the prescription opioid abuse epidemic. Prescriber use mandates has emerged as a promising practice to increase PDMPs impact on prescription opioid abuse; however, evidence of its effectiveness has not yet been established. Kentucky was the first state to implement comprehensive prescriber use mandates in July 2012. Objective: To assess the relationship between prescriber use mandates policy and emergency department (ED) visits related to prescription opioid poisoning among adults in Kentucky and North Carolina. Secondary aim: to evaluate the economic impact of prescriber use mandates in Kentucky. Methods: A controlled, pre-post study design. Data from the State Emergency Department Databases (SEDD) and the State Inpatient databases (SID) were used to identify prescription opioid poisoning ED visits among those [greater or equal to] 12 years old. Prevalence rate were estimated. Prescription opioid poisoning ED visits were characterized based on sociodemographic and clinical characteristics. Logistic regression was applied to compare occurrences of prescription opioid poisoning ED visits pre and post prescriber use mandates in Kentucky, and between Kentucky and North Carolina for the period 2011 to 2014. A cost of illness framework was applied to estimate direct medical costs associated with prescription opioid poisoning ED visits. The economic impact of prescriber use mandates was quantified based on logistic regression coefficient for the interaction term (state*time to implementation). Results: There were 7,419 and 12,598 prescription opioid poisoning -related ED visits in Kentucky and North Carolina, respectively. Young and Middle age, male gender, white, having one or more chronic conditions, and psychiatric conditions (such as depression and drug abuse) were significantly associated with prescription opioid poisoning ED visits (p-value







Medications for Opioid Use Disorder Save Lives


Book Description

The opioid crisis in the United States has come about because of excessive use of these drugs for both legal and illicit purposes and unprecedented levels of consequent opioid use disorder (OUD). More than 2 million people in the United States are estimated to have OUD, which is caused by prolonged use of prescription opioids, heroin, or other illicit opioids. OUD is a life-threatening condition associated with a 20-fold greater risk of early death due to overdose, infectious diseases, trauma, and suicide. Mortality related to OUD continues to escalate as this public health crisis gathers momentum across the country, with opioid overdoses killing more than 47,000 people in 2017 in the United States. Efforts to date have made no real headway in stemming this crisis, in large part because tools that already existâ€"like evidence-based medicationsâ€"are not being deployed to maximum impact. To support the dissemination of accurate patient-focused information about treatments for addiction, and to help provide scientific solutions to the current opioid crisis, this report studies the evidence base on medication assisted treatment (MAT) for OUD. It examines available evidence on the range of parameters and circumstances in which MAT can be effectively delivered and identifies additional research needed.




Prescription Drug Monitoring


Book Description